Otonomy (OTIC) Tops Q1 EPS by 4c

Go back to Otonomy (OTIC) Tops Q1 EPS by 4c

Otonomy Reports First Quarter 2019 Financial Results and Provides Corporate Update

May 6, 2019 4:17 PM EDT

OTO-313 Phase 1/2 trial in tinnitus initiated; results expected in first half of 2020OTIPRIO® co-promotion agreement completed with Glenmark TherapeuticsOTIVIDEX Phase 3 trial in Ménières disease on track for results in first half of 2020 OTO-413 Phase 1/2 trial in hearing loss expected to start in third quarter of 2019; results expected in second half of 2020Current capital funds operations into... More